Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United KingdomIPO:
08 September 2020Next earnings report:
16 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 5 min agoDividend
Analysts recommendations
Institutional Ownership
SLN Latest News
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peoples' lives by silencing diseases through precision engineered medicines, today announced that it will receive a $2.0 million cash payment from Hansoh Pharmaceutical Group Company Limited (“Hansoh”) following the achievement of a second undisclosed milestone related to the first target under the collaboration. “This represe.
Silence Therapeutics plc results from the phase 1 SANRECO study, using divesiran for the treatment of patients with polycythemia vera, expected end of June 2024. The 7 major polycythemia vera markets are expected to reach $68.5 billion by 2034. Positive results achieved in the phase 2 ALPACAR-360 study using zerlasiran for patients with elevated levels of Lp[a] at high risk of ASCVD.
Silence Therapeutics (SLN) experienced a significant increase in its stock price during the last trading session, with above-average trading volume. The recent changes in earnings estimates suggest that there may be additional price growth in the near future.
Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript
Silence Therapeutics PLC Sponsored ADR (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Topline 36-week data from the phase 2 ALPACAR-360 study using its drug zerlasiran for patients with high lipoprotein[a] and stable atherosclerotic cardiovascular disease, expected in Q1 2024. There are four other data readouts/presentations expected in 2024, which relate to the use of zerlasiran for the treatment of patients with high lipoprotein[a] and stable atherosclerotic cardiovascular disease. The global cardiovascular disease drugs' market size is expected to reach $186.1 billion by 2032; Targeting lipoprotein[a] for cardiovascular disease is an unmet need.
Silence Therapeutics PLC Sponsored ADR (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Silence Therapeutics PLC Sponsored ADR (SLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
If you are looking for stocks that are well positioned to maintain their recent uptrend, Silence Therapeutics PLC Sponsored ADR (SLN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Silence Therapeutics PLC Sponsored ADR (SLN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
What type of business is Silence Therapeutics?
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
What sector is Silence Therapeutics in?
Silence Therapeutics is in the Healthcare sector
What industry is Silence Therapeutics in?
Silence Therapeutics is in the Biotechnology industry
What country is Silence Therapeutics from?
Silence Therapeutics is headquartered in United Kingdom
When did Silence Therapeutics go public?
Silence Therapeutics initial public offering (IPO) was on 08 September 2020
What is Silence Therapeutics website?
https://www.silence-therapeutics.com
Is Silence Therapeutics in the S&P 500?
No, Silence Therapeutics is not included in the S&P 500 index
Is Silence Therapeutics in the NASDAQ 100?
No, Silence Therapeutics is not included in the NASDAQ 100 index
Is Silence Therapeutics in the Dow Jones?
No, Silence Therapeutics is not included in the Dow Jones index
When does Silence Therapeutics report earnings?
The next expected earnings date for Silence Therapeutics is 16 August 2024